Obinutuzumab in Rituximab-Resistant Podocytopathies: A Single-Center Experience

Obinutuzumab in Rituximab-Resistant Podocytopathies: A Single-Center Experience

Saved in:

Bibliographic Details
Main Authors:	Andrea Angeletti, Gianluca Caridi, Xhuliana Kajana, Carolina Bigatti, Agnese Spennacchio, Decimo Silvio Chiarenza, Gabriele Mortari, Paolo Cravedi, Enrico E. Verrina
Format:	Article
Language:	English
Published:	Elsevier 2025-08-01
Series:	Kidney International Reports
Online Access:	http://www.sciencedirect.com/science/article/pii/S2468024925003894
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Efficacy and Safety of Subcutaneous Rituximab in Idiopathic Nephrotic Syndrome
by: Paolo Cravedi, et al.
Published: (2024-11-01)

Combined Rituximab and Daratumumab Treatment in Difficult-to-Treat Nephrotic Syndrome Cases
by: Andrea Angeletti, et al.
Published: (2024-06-01)

Case report: Single infusion of combined anti-CD20 and anti-CD38 monoclonal antibodies in pediatric refractory lupus nephritis
by: Decimo Silvio Chiarenza, et al.
Published: (2025-01-01)

WCN25-3004 ANTi-NEPHRIN ANTIBODIES IN A LARGE COHORT OF PATIENTS WITH IDIOPATHIC NEPHROTIC SYNDROME
by: Andrea Angeletti, et al.
Published: (2025-02-01)

Obinutuzumab in Rituximab-Intolerant Antineutrophil Cytoplasmic Antibody–Associated Vasculitis Patients
by: Jolijn R. van Leeuwen, et al.
Published: (2025-04-01)

Obinutuzumab and Ofatumumab are More Effective Than Rituximab in the Treatment of Membranous Nephropathy Patients With Anti-Rituximab Antibodies
by: Maxime Teisseyre, et al.
Published: (2025-03-01)

WCN24-2512 LUPUS PODOCYTOPATHY: CASE REPORT
by: Alexandre Salvatore Pipino, et al.
Published: (2024-04-01)

WCN25-1329 Randomised controlled trial comparing rituximab to mycophenolate mofetil in children and young adults with steroid-dependent idiopathic nephrotic syndrome
by: Andrea Angeletti, et al.
Published: (2025-02-01)

Diffuse Podocytopathy Associated With Semaglutide
by: Rose Mary Attieh, et al.
Published: (2024-05-01)

Roxadustat: More Than an Erythropoietic Agent?
by: Andrea Angeletti, et al.
Published: (2025-01-01)

Debulking Therapy with Obinutuzumab Is Helpful and Safe in Chronic Lymphocytic Leukemia with Extreme Hyperleukocytosis: A Case Report
by: Dario Leotta, et al.
Published: (2025-03-01)

WCN24-802 ALPORT SYNDROME WITH PODOCYTOPATHY
by: NIHAL BASHIR, et al.
Published: (2024-04-01)

Non-invasive Diagnosis of Antinephrin–Associated Podocytopathy
by: Felicitas E. Hengel, et al.
Published: (2025-08-01)

The importance of detection of autoantibodies to podocytes in primary podocytopathies
by: Evgenia A. Kharionovskaya, et al.
Published: (2025-01-01)

Research status and recent advances of lupus podocytopathy
by: Yang Meng, et al.
Published: (2021-01-01)

Study protocol for a randomised, phase II, double-blind, experimental medicine study of obinutuzumab versus rituximab in ANCA-associated vasculitis: ObiVas
by: Simon Bond, et al.
Published: (2024-07-01)

Effectiveness and Safety of Polatuzumab Vedotin Plus an Anti‐CD20 Monoclonal Antibody (Rituximab or Obinutuzumab) and Zanubrutinib in Relapsed/Refractory Diffuse Large B‐Cell Lymphoma
by: Yian Zhang, et al.
Published: (2025-08-01)

The Occurrence of Richter’s Syndrome during Treatment with Obinutuzumab and Chlorambucil
by: Teng Fong Ng, et al.
Published: (2020-01-01)

Complement and Podocytopathies: Do We Have a New Biomarker?
by: Miquel Blasco, et al.
Published: (2024-03-01)

Organising Pneumonia in a Patient Following Obinutuzumab for Follicular Lymphoma
by: Viral Nanda, et al.
Published: (2025-06-01)

Obinutuzumab for Relapsing Myeloperoxidase-Antineutrophil Cytoplasmic Autoantibody–Associated Glomerulonephritis
by: Michael Cammarata, et al.
Published: (2025-06-01)

Autoantibodies Targeting Vinculin Reveal Novel Insight into the Mechanisms of Autoimmune Podocytopathies
by: Hanyan Meng, et al.
Published: (2025-01-01)

WCN24-2640 HISTOLOGICAL TRANSITION IN LUPUS PODOCYTOPATHY: REPORT OF TWO CASES
by: Alfredo Fonseca-Chavez, et al.
Published: (2024-04-01)

WCN24-1436 COLLAPSING LUPUS PODOCYTOPATHY, UNLIKE OTHER COLLAPSING GLOMERULOPATHIES?
by: Elisa Mendoza, et al.
Published: (2024-04-01)

Obinutuzumab as Initial or Second-Line Therapy in Patients With Primary Membranous Nephropathy
by: Xiaole Su, et al.
Published: (2024-08-01)

Obinutuzumab-induced acute thrombocytopenia: a case report and literature review
by: Xuelin Dou, et al.
Published: (2024-12-01)

Obinutuzumab en glomerulonefritis focal y segmentaria resistente al tratamiento
by: Byron Chiliquinga Morales, et al.
Published: (2025-04-01)

Treatment with obinutuzumab plus venetoclax reshapes the TRB repertoire of CLL patients
by: Paul J. Hengeveld, et al.
Published: (2025-01-01)

WCN24-2478 PODOCYTOPATHY ASSOCIATED WITH IGA NEPHROPATHY: IS IT REALLY A PROGNOSTIC FACTOR?
by: BELENGALLEGOS VAZQUEZ, et al.
Published: (2024-04-01)

The differential expression of MAGI2 in glomerulopathies and its application as a molecular discriminator of podocytopathies
by: Florian Siegerist, et al.
Published: (2025-06-01)

Minimal Change Podocytopathy with Coexistent Thin Glomerular Basement Membrane following Exposure to Semaglutide
by: Karthik Kovvuru, et al.
Published: (2025-01-01)

Obinutuzumab-induced severe acute thrombocytopenia: a case report and literature review
by: Kun Kou, et al.
Published: (2025-08-01)

What’s new in medical renal pathology 2025: Updates on podocytopathy and immunofluorescence staining in medical kidney
by: Astrid Weins, et al.
Published: (2025-07-01)

WCN24-1435 LUPUS PODOCYTOPATHY: CASE SERIES OF 4 CASES FROM DOMINICAN REPUBLIC
by: Eliana Dina-Batlle, et al.
Published: (2024-04-01)

Efficacy and safety of obinutuzumab in primary membranous nephropathy: a real-world retrospective study
by: Xi Cheng, et al.
Published: (2025-08-01)

Obinutuzumab is Effective as an Initial Treatment for PLA2R-Associated Primary Membranous Nephropathy: A Retrospective, Single-Center Trial
by: Li XQ, et al.
Published: (2025-07-01)

WCN25-1613 GLUCOCORTICOID TOXICITY INDEX IN MEMBRANOUS NEPHROPATHY AND PODOCYTOPATHIES IN ADULT: A PILOT STUDY
by: RAJESH KUMAR, et al.
Published: (2025-02-01)

WCN25-3992 EFFACED BUT NOT ERASED - A CASE OF CONSECUTIVE RELAPSES OF LUPUS PODOCYTOPATHY IN RENAL TRANSPLANTS
by: Renuka Tolani, et al.
Published: (2025-02-01)

WCN24-420 SAFETY AND EFFICACY OF ANIFROLUMAB IN IMMUNE COMPLEX AND APOL-1 ASSOCIATED LUPUS PODOCYTOPATHY
by: James Tumlin, et al.
Published: (2024-04-01)

Markers of inflammation, fibrosis, endothelial dysfunction, and podocytopathy in patients with long-term type 1 diabetes mellitus
by: M. I. Yevloyeva, et al.
Published: (2025-05-01)